RxDoctor Payments Data

Ivette Rosario Robles, MD

Internal Medicine · San Juan, PRNPI 1558475194

Payments from drug & device makers

$2,309in general payments, 2019–2025

Across 136 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$440
  • AstraZeneca$436
  • GSK$217
  • Amarin Pharma, Inc.$140
  • Novo Nordisk$134
  • Amgen$128
  • plus $815 from 15 others

What the payments were for

  • Food & beverage$2,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,309 in reported general payments places this provider in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$23,738
Medicare patients
77
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$33,305
JanuviaSitagliptin Phosphate21$28,328
TrulicityDulaglutide23$24,243
JanumetSitagliptin Phos/Metformin Hcl23$20,306
EliquisApixaban11$14,463
MounjaroTirzepatide13$13,349
FarxigaDapagliflozin Propanediol12$13,231
MyrbetriqMirabegron17$9,801
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$8,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,285
SymbicortBudesonide/Formoterol Fumarate19$5,679
LantusInsulin Glargine,hum.Rec.Anlog31$5,323
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,279
Atorvastatin Calcium544$4,496
Rosuvastatin Calcium400$3,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$23$48,63444 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$440$40,10749 claims
Boehringer IngelheimJardiance$93$33,30529 claims
AstraZenecaFarxiga, Symbicort$436$18,91031 claims
PfizerEliquis$85$14,46311 claims
Astellas Pharma US IncMyrbetriq$29$9,80117 claims
GSKTrelegy Ellipta$217$7,28512 claims
AbbVieSynthroid$52$2,07615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →